Steven Alberts, MD
Enriched profileChair of Medical Oncology and Professor of Oncology, Mayo Clinic · Mayo Clinic Minnesota
Steven Alberts is Chair of Medical Oncology and Professor of Oncology, Mayo Clinic at Mayo Clinic Minnesota. OpenAlex indexes 472 publications with 24,526 citations (h-index 74); ClinicalTrials.gov lists 19 registered studies with this person as an investigator.
Data verified 18 Oct 2026
Overview
Updated 18 Oct 2026
Steven Alberts, M.D., is Chair of Medical Oncology and Professor of Oncology, Mayo Clinic at Mayo Clinic Minnesota. The public record shows 472 publications with 24,526 citations (h-index 74), centered on Colorectal Cancer Treatments and Studies, Colorectal Cancer Surgical Treatments, Genetic factors in colorectal cancer. It also documents an investigator role on 19 registered clinical trials, industry payments reported by 2 companies, 6 NIH-funded awards (1999–2023).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Colorectal Cancer Treatments and Studies
- 19 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 11 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 211.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 19 registered studies on ClinicalTrials.gov. The most recent:
- Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Sponsor: Alliance for Clinical Trials in Oncology
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Sponsor: Alliance for Clinical Trials in Oncology
Industry payments
Updated 18 Oct 2026
2 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20251 payment
- Merck Sharp & Dohme LLCProgram year20241 payment
- Merck Sharp & Dohme LLCProgram year20231 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
72.7%PD-1 inhibitor43.2%Pembrolizumab100%Part B, office-administered≥16 patientsCD38-directed Cytolytic Antibody24.1%Daratumumab100%Part B, office-administered≥12 patients+ 1 more class in this area
Metabolism & gastrointestinal
22.4%Other antiemetics17%Fosaprepitant100%Part B, office-administered≥11 patientsSerotonin-3 Receptor Antagonist4.8%Palonosetron hcl56%Ondansetron hydrochloride33%Ondansetron Hcl12%Part D + Part B≥35 patients+ 3 more classes in this area
Sensory organs
3.7%Corticosteroid3.7%Dexamethasone sodium phosphate83%Dexamethasone17%Part D + Part B≥26 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
6 NIH research awards on record, funded 1999–2023 per NIH RePORTER. The latest:
- NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1
Mayo Clinic Rochester
FY2023$867,908UG1CA232760 - NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1
Mayo Clinic Rochester
FY2022$931,004UG1CA232760 - Project 3: Inhibition of SCD1 as a therapeutic strategy for HCC
Mayo Clinic Rochester
FY2022$358,289P50CA210964
Congress activity
Updated 18 Oct 2026
138 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract 5070: Tumor spatial configuration predicts pancreatic cancer recurrence risk after total neoadjuvant therapy
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147).
Journal of clinical oncology
Clinical Trial2026 - Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials.
Journal of clinical oncology
Article2024 - Use of Deep Learning to Evaluate Tumor Microenvironmental Features for Prediction of Colon Cancer Recurrence.
Cancer research communications
Article2024 - Impact of the Immediate Release of Clinical Information Rules on Health Care Delivery to Patients With Cancer.
JCO oncology practice
Article2023
Most-cited works
by citation count (OpenAlex)Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/steven-alberts-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doctor.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mayo.edu ↗
Editorial & leadership roles
journal and society appointments- Co-chair
Pancreatic Cancer Subcommittee, Alliance for Clinical Trials in Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doctor.com ↗ - Member
Gastrointestinal Intergroup GI Steering Committee, National Cancer Institute
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doctor.com ↗ - Member
PCLI Steering Committee, AACI (Physician Clinical Leadership Initiative)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aaci-cancer.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctor.com ↗
Media & interviews
press, podcasts and appearances- Contributing author
OncLive (gastrointestinal malignancies focus)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH